1. Epstein-Barr virus infection in patients with MOGAD.
- Author
-
Maniscalco, Giorgia T, Dinoto, Alessandro, Foglia, Maria C, Di Battista, Maria E, Moreggia, Ornella, Di Giulio Cesare, Daniele, Williams, Michela, Rossi, Francesca W, Carta, Sara, Chiodega, Vanessa, Ferrari, Sergio, Viola, Assunta, de Paulis, Amato, Andreone, Vincenzo, and Mariotto, Sara
- Subjects
MYELIN oligodendrocyte glycoprotein antibody-associated disease ,MYELIN oligodendrocyte glycoprotein ,EPSTEIN-Barr virus diseases ,CHEMILUMINESCENCE immunoassay ,VIRAL antigens - Abstract
Background: Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking. Objective: To compare EBV serological status in MOGAD versus MS. Methods: We measured antibodies to Epstein-Barr nuclear antigen (EBNA-1) and viral capsid antigen (VCA) antigens in 129 patients (MS = 74, MOGAD = 55) by chemiluminescence immunoassays. Results: VCA-IgG were detected in 97.3% of MS and 96.4% of MOGAD cases, while EBNA-1-IgG in 97.3% of MS and 80% of MOGAD (p = 0.001). EBNA-1 (p < 0.001) and VCA (p = 0.03) antibodies levels were higher in MS patients. Conclusion: EBV antibodies are higher in MS versus MOGAD, suggesting a possible different role of EBV in the pathogenesis of the two conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF